This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
I'm LongbridgeAI, I can summarize articles.Wall Street analysts initiated coverage on five biotech and tech stocks with bullish or neutral outlooks. BMO's David Lebowitz rated Alnylam (ALNY) Outperform ($318 PT), BioMarin (BMRN) Outperform ($98 PT), and Ionis (IONS) Market Perform ($60 PT). Cantor Fitzgerald rated AgomAb (AGMB) Overweight, while CLSA rated KE Holdings (BEKE) Outperform ($23.8 PT). These initiations reflect updated analyst opinions on the respective companies.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- BMO Capital analyst David Lebowitz initiated coverage on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) with an Outperform rating and announced a price target of $318. Alnylam Pharmaceuticals closed at $228.61 on Tuesday. See how other analysts view this stock.
- Cantor Fitzgerald analyst Yanni Souroutzidis initiated coverage on Agomab Therapeutics NV (NASDAQ:AGMB) with an Overweight rating. AgomAb Therapeutics shares closed at $13.73 on Tuesday. See how other analysts view this stock.
- BMO Capital analyst David Lebowitz initiated coverage on Biomarin Pharmaceutical Inc (NASDAQ:BMRN) with an Outperform rating and announced a price target of $98. BioMarin Pharmaceutical closed at $66.99 on Tuesday. See how other analysts view this stock.
- CLSA analyst Alvin Huang initiated coverage on KE Holdings Inc – ADR (NYSE:BEKE) with an Outperform rating and announced a price target of $23.8. KE Holdings shares closed at $16.87 on Tuesday. See how other analysts view this stock.
- BMO Capital analyst David Lebowitz initiated coverage on Ionis Pharmaceuticals Inc (NASDAQ:IONS) with a Market Perform rating and announced a price target of $60. Ionis Pharmaceuticals closed at $59.62 on Tuesday. See how other analysts view this stock.
Considering buying ALNY stock? Here’s what analysts think:
Photo via Shutterstock